429 related articles for article (PubMed ID: 8232694)
1. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.
Bichet DG; Razi M; Lonergan M; Arthus MF; Papukna V; Kortas C; Barjon JN
N Engl J Med; 1988 Apr; 318(14):881-7. PubMed ID: 2965301
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus.
Knoers N; Brommer EJ; Willems H; van Oost BA; Monnens LA
Nephron; 1990; 54(4):322-6. PubMed ID: 2109264
[TBL] [Abstract][Full Text] [Related]
4. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs.
Bernat A; Hoffmann P; Dumas A; Serradeil-le Gal C; Raufaste D; Herbert JM
J Pharmacol Exp Ther; 1997 Aug; 282(2):597-602. PubMed ID: 9262320
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
[TBL] [Abstract][Full Text] [Related]
6. Normal homeostasis of fibrinolysis in nephrogenic diabetes insipidus in spite of defective V2- receptor-mediated responses of tissue plasminogen activator release.
Brommer EJ; Brink H; Derkx FH; Schalekamp MA; Stibbe J
Eur J Clin Invest; 1990 Feb; 20(1):72-8. PubMed ID: 2138555
[TBL] [Abstract][Full Text] [Related]
7. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
Sultan Y; Loyer F; Venot A
Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
[TBL] [Abstract][Full Text] [Related]
8. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
9. Normal response of factor VIII and von Willebrand factor to 1-deamino-8D-arginine vasopressin in nephrogenic diabetes insipidus.
Brenner B; Seligsohn U; Hochberg Z
J Clin Endocrinol Metab; 1988 Jul; 67(1):191-3. PubMed ID: 3132483
[TBL] [Abstract][Full Text] [Related]
10. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
[TBL] [Abstract][Full Text] [Related]
11. Effects of arginine vasopressin and 1-desamino-8-D arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect.
van Lieburg AF; Knoers NV; Monnens LA; Smits P
J Hypertens; 1995 Dec; 13(12 Pt 2):1695-700. PubMed ID: 8903635
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macaca mulatta).
Kinter LB; McConnell I; Goodwin BT; Campbell S; Huffman WF; Arthus MF; Lonergan M; Bichet DG
J Pharmacol Exp Ther; 1992 May; 261(2):462-9. PubMed ID: 1578361
[TBL] [Abstract][Full Text] [Related]
13. Lack of responsiveness to 1-desamino-D arginin vasopressin (desmopressin) in male patients with nephrogenic syndrome of inappropriate antidiuresis: from bench to bedside.
Vandergheynst F; Pradier O; Beukinga I; Kornreich A; Vassart G; Decaux G
Eur J Clin Invest; 2012 Mar; 42(3):254-9. PubMed ID: 21834801
[TBL] [Abstract][Full Text] [Related]
14. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ
Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642
[TBL] [Abstract][Full Text] [Related]
15. DDAVP (1-desamino-8-D-arginine vasopressin): an antagonist of the pressor action of endogenous vasopressin?
Derkx FH; Man in 't Veld AJ; Jones R; Reid JL; Schalekamp MA
J Hypertens Suppl; 1983 Dec; 1(2):58-61. PubMed ID: 6400119
[TBL] [Abstract][Full Text] [Related]
16. Two distinct pathophysiological mechanisms in congenital nephrogenic diabetes insipidus.
Moses AM; Miller JL; Levine MA
J Clin Endocrinol Metab; 1988 Jun; 66(6):1259-64. PubMed ID: 3131381
[TBL] [Abstract][Full Text] [Related]
17. Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin-6.
Newby DE; Stewart A; Witherow FN; Grieve S; Dawson P; Fox KA; Webb DJ; Ludlam CA
Thromb Haemost; 2000 Aug; 84(2):195-203. PubMed ID: 10959689
[TBL] [Abstract][Full Text] [Related]
18. The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients--analysis of responders and non-responders.
Brommer EJ; Barrett-Bergshoeff MM; Allen RA; Schicht I; Bertina RM; Schalekamp MA
Thromb Haemost; 1982 Oct; 48(2):156-61. PubMed ID: 6817444
[TBL] [Abstract][Full Text] [Related]
19. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
Wieczorek I; Ludlam CA; MacGregor IR
Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
[TBL] [Abstract][Full Text] [Related]
20. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion.
Keber D; Stegnar M; Kluft C
Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
